


EVOLUTION OF TREATMENT CONSUMPTION IN SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS (2018-2023)

E Paradela, M Florido Francisco, A Romero, E Sánchez Gómez

Hospital Pharmacy. Juan Ramon Jimenez University Hospital. Ronda Norte Avenue, n/n, 21005 Huelva, Spain.

BACKGROUND AND IMPORTANCE

Secondary-progressive multiple sclerosis (SPMS) is a clinical phenotype that develops in about 50% of patients with relapsing-remitting multiple sclerosis (RRMS). There is a **progressive worsening** of symptoms without remission periods and progression may not present outbreaks.



AIM AND OBJECTIVES


The aim of our study is to compare the **variation in consumption patterns** of SPMS drugs dispensed in a Hospital Pharmacy Service during the 2018-2023 period.

MATERIAL AND METHODS

This was a retrospective, single-centre and observational study, conducted from **2018-2023**. The comparison of treatment consumption was carried out by calculating the defined **daily doses (DDD)/1000 inhabitants/day** through the DDD established by the *WHO Collaborating Centre*, the information provided by the Athos-Stock program and the census of inhabitants of the hospital area.

RESULTS

DRUG	ADMIN	LINE	2018	2019	2020	2021	2022	2023
SIPONIMOD 2 mg	VO	1ª	0	0	0	0,0083	0,0311	0,0380
INTERFERÓN BETA 1B 250 mcg (Extavia)	SC	1ª	0,0229	0,0224	0,0139	0,0115	0,0088	0,0082
INTERFERÓN BETA 1A 22/44 mcg (Rebif)	SC	1ª	0,0119	0,0162	0,0088	0,0110	0,0087	0,0104
OFATUMUMAB 20 mg	SC	1ª	0	0	0	0	0,0021	0,0234



CONCLUSION AND RELEVANCE

The consumption of **IFN-based** older treatments has shown a gradual **decrease** over the last 6 years, coinciding with an **increase** in the consumption of the **new available** therapeutic options. The appearance of **siponimod** has displaced the previous treatments indicated for SPMS, making it the most widely used drug in 2023. We expect that this **increasing consumption** will continue, favored by the scarcity of alternatives for this clinical phenotype.



COP
ENHA
GEN
2025

29TH EAHP CONGRESS
12-13-14 MARCH
PERSON CENTRED PHARMACY -
NAVIGATING DIGITAL HEALTH



2SPD-003

